Drug Trial Radar · NCT02304393
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Dec 12, 2014
Primary completion
Nov 7, 2019
Study completion Nov 7, 2019
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or locally advanced solid tumors. The study will be conducted in two Parts (I and II), with Part I divided into Parts IA and IB. All participants will be followed up for survival until death or loss of follow-up after the last visit or withdrawal of consent.
Conditions
- Solid Tumors
Interventions
AtezolizumabDrug
Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
SelicrelumabDrug
Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part IA: Percentage of Participants with Adverse Events and Serious Adverse EventsTime frame: Baseline up to 28 Days After the Last Dose (Approximately 38 Months)
- Part IB: Percentage of Participants with Adverse Events and Serious Adverse EventsTime frame: Baseline up to 28 Days After the Last Dose (Approximately 38 Months)
- Part IB: Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)
- Part IB: Maximum Tolerated Dose (MTD) of SelicrelumabTime frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)
- Part IB: Recommended Part II Dose of SelicrelumabTime frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)
- Part II: Percentage of Participants with Adverse Events and Serious Adverse EventsTime frame: Baseline up to 28 days after the last dose (approximately 38 months)
- Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Progression-Free Survival (PFS), as Determined by Investigator Using RECIST Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Duration of Objective Response, as Determined by Investigator Using RECIST Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Percentage of Participants With Disease Control, as Determined by Investigator Using RECIST Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Percentage of Participants With Disease Control, as Determined by Investigator Using Unidimensional irRCTime frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: PFS, as Determined by Investigator Using Unidimensional irRCTime frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Unidimensional Immune-Related Response Criteria (irRC)Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Duration of Objective Response, as Determined by Investigator Using Unidimensional irRCTime frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
- Part II: Overall SurvivalTime frame: Baseline up to death due to any cause (up to approximately 38 months)
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
University of Pennsylvania
Philadelphia, Pennsylvania
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
Toronto, Ontario, Canada
Jewish General Hospital / McGill University
Montreal, Quebec, Canada
Rigshospitalet; Onkologisk Klinik
København Ø, Denmark
Aphm; Cpcet
Marseille, France
Hopital Saint Louis, Service D Oncologie Medicale
Paris, France
Institut Gustave Roussy; Sitep
Villejuif, France
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed
Rotterdam, Netherlands
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.